Bluejay Investor Presentation Deck

Board of Directors Douglas C. Wurth Chairman ●●● Indranil "Neil" Dey CEO Svetlana Dey Donald R. Chase Fred S. Zeidman Gary Gemignani J.P.Morgan Skadden bluejay DIAGNOSTICS ● ● ● ● ● ● ● ● 20 year career at J.P. Morgan Chase (CEO of the International Private Bank & Alternative Investments, Asset Management) B.A Notre Dame University; J.D. University of Virginia School of Law, practiced law at Skadden, Arps, Meagher and Flom Involved in introducing Her2neu test for Herceptin (>$1.2 billion revenue) and introduction of Erbitux (>$1.15 billion revenue) Ph.D. in Biochemistry (UNESCO fellow) from BRC, Hungary and MBA (Fulbright Scholar) from Cambridge University, UK Co-founder of Bluejay, President & CEO of LMBRI LLC, 15 years+ of management experience in healthcare industry Masters Degree in Mathematics from the State University of Mari El Republic, Russia 35 years, Executive roles in well-known community banks in Springfield, MA. and Nashua, NH B.S., Accounting, Western New England University, Springfield, MA 50+ years of corporate advisory experience. Chairman Emeritus University of Texas Health Science System Bachelor's degree from Washington University in St. Louis and a Master's in Business Administration from New York University Experience in life sciences, public companies, accounting/finance. Senior executive/leadership roles starting at Arthur Anderson & Co Also Acacia Pharma Group plc, Biodel Inc., Prudential Financial, Gentium, Novartis, Wyeth Imbri IMPATH The Cancer Information Company LAMINAR PHARMA merchants BANCSHARES INC westbank ARTHUR ANDERSEN UNITED STA MEMORIAL HOLOCAUST MUSEUM Copyright ©2022 Bluejay Diagnostics, Inc. All rights reserved in all slides | September 2022 17

View entire presentation